Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
+1.15%-2.81%+53.73%+71.00% 65.56B
-2.42%-0.81%+8.18%+89.52% 60.41B
-1.04%+0.27%+22.88%+86.70% 55.76B
-0.63%-3.65%+8.47%+118.60% 46.98B
-1.96%-5.90%+19.80%+26.43% 43.63B
-0.70%+1.43%+14.05%+45.20% 36.7B
-2.59%-16.03%+134.48%+660.06% 36.09B
-0.77%-2.26%+77.17%+57.87% 32.9B
-2.61%-0.46%-39.75%+379.21% 26.96B
Average -0.58%-1.71%+33.22%+170.51% 45B
Weighted average by Cap. -1.11%-1.48%+33.06%+146.25%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-